Anavex Life Sciences (AVXL) Stock Price, News & Analysis

Company Overview

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Key Stats

• Today's Range: $9.28 to $9.78
• 50-Day Range: $7.37 to $9.63
• 52-Week Range: $4.00 to $14.44
• Volume: 2.82 million shs
• Average Volume: 1.18 million shs
• Market Capitalization: $809.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.00
• Consensus Rating: Buy

Anavex Life Sciences Stock Analysis - MarketRank™

Anavex Life Sciences scored higher than 77% of companies evaluated by MarketBeat, and ranked 249th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Anavex Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Anavex Life Sciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Anavex Life Sciences are expected to grow in the coming year, from ($0.69) to ($0.66) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Anavex Life Sciences is -17.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Anavex Life Sciences is -17.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Anavex Life Sciences has a P/B Ratio of 6.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

33.33% of the float of Anavex Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Anavex Life Sciences has a short interest ratio ("days to cover") of 26.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Anavex Life Sciences has recently increased by 0.72%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Anavex Life Sciences does not currently pay a dividend.

Dividend Growth

Anavex Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.83

Percentage of Shares Shorted

33.33% of the float of Anavex Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Anavex Life Sciences has a short interest ratio ("days to cover") of 26.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Anavex Life Sciences has recently increased by 0.72%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.28

News Sentiment

Anavex Life Sciences has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Anavex Life Sciences this week, compared to 4 articles on an average week.

Search Interest

Only 5 people have searched for AVXL on MarketBeat in the last 30 days. This is a decrease of -84% compared to the previous 30 days.

MarketBeat Follows

6 people have added Anavex Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Anavex Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.00% of the stock of Anavex Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 31.55% of the stock of Anavex Life Sciences is held by institutions.

AVXL Stock Analysis - Frequently Asked Questions

How have AVXL shares performed this year?

Anavex Life Sciences' stock was trading at $10.74 at the start of the year. Since then, AVXL stock has decreased by 11.7% and is now trading at $9.48.
View the best growth stocks for 2025 here.

How were Anavex Life Sciences' earnings last quarter?

Anavex Life Sciences Corp. (NASDAQ:AVXL) released its quarterly earnings data on Tuesday, May, 13th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03.
Read the conference call transcript.

Who are Anavex Life Sciences' major shareholders?

Top institutional investors of Anavex Life Sciences include Vanguard Group Inc. (5.74%), Nwam LLC (1.17%), Charles Schwab Investment Management Inc. (0.78%) and Invesco Ltd. (0.65%). Insiders that own company stock include Christopher U Missling, Steffen Thomas and Peter DO Donhauser.
View institutional ownership trends.

How do I buy shares of Anavex Life Sciences?

Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Anavex Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Anavex Life Sciences investors own include Symbotic (SYM), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Mesa Air Group (MESA), Innovative Industrial Properties (IIPR), Voya Infrastructure, Industrials and Materials Fund (IDE), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 6/29/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AVXL
• CIK: 1314052
• Web: www.anavex.com
• Phone: (844) 689-3939
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $44.00
• High Stock Price Target: $46.00
• Low Stock Price Target: $42.00
• Potential Upside/Downside: +364.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$43 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -40.93%
• Return on Assets: -36.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.74
• Quick Ratio: 6.74

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.42 per share
• Price / Book: 6.68

Miscellaneous

• Outstanding Shares: 85,370,000
• Free Float: 75,981,000
• Market Cap: $809.31 million
• Optionable: Optionable
• Beta: 0.68